Genetic variations associated with drug resistance
US11021711B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2017 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | Dec 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/106
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.